Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.

RPEP-086342024Lawitz, Eric J; Fraessdorf, Mandy; Neff, Guy W; Schattenberg, Jörn M; Noureddin, Mazen; Alkhouri, Naim; Schmid, Bernhard; Andrews, Charles P; Takács, István; Hussain, Samina Ajaz; Fenske, Wiebke K; Gane, Edward J; Hosseini-Tabatabaei, Azadeh; Sanyal, Arun J; Mazo, Daniel F; Younes, Ramy

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.

Journal of hepatology, 81(5), 837-846

View on PubMed ↗Publisher’s paper ↗

Citation

Lawitz, Eric J; Fraessdorf, Mandy; Neff, Guy W; Schattenberg, Jörn M; Noureddin, Mazen; Alkhouri, Naim; Schmid, Bernhard; Andrews, Charles P; Takács, István; Hussain, Samina Ajaz; Fenske, Wiebke K; Gane, Edward J; Hosseini-Tabatabaei, Azadeh; Sanyal, Arun J; Mazo, Daniel F; Younes, Ramy. (2024). Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.. Journal of hepatology, 81(5), 837-846. https://doi.org/10.1016/j.jhep.2024.06.003